Please login to the form below
omalizumab
This page shows the latest omalizumab news and features for those working in and with pharma, biotech and healthcare.
Novartis reveals positive efficacy data for Xolair follow-up
older immunology drug Xolair (omalizumab). .
Latest news
-
China updates drug reimbursement list, agrees price cuts
The key drugs which have been added to the list include AbbVie’s blockbuster drug Humira (adalimumab), Novartis’ dermatitis drug Xolair (omalizumab) and Roche’s HER2 breast cancer treatment Perjeta (petuzumab).
-
FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps
Roche and Novartis’ severe asthma therapy Xolair (omalizumab) has data showing it is effective as a treatment for polyps, but isn’t expected to be approved until the end of next
-
Novartis claims first place for psoriasis drug Cosentyx in China
The firm has recently picked up Chinese approvals for a clutch of therapies including Xolair (omalizumab) for asthma and heart failure therapy Entresto (valsartan/sacubitril).
-
FDA gives breakthrough status to Xolair for food allergies
The US regulator awarded Xolair (omalizumab) the coveted status for the prevention of severe allergic reactions following accidental exposure to one or more foods in people with allergies, opening up another
-
AZ prices severe asthma drug Fasenra below competition
Along with Nucala and Cinqair, severe asthma patients can also be treated with Novartis’ older drug Xolair (omalizumab), although that is indicated for allergic asthma and doesn’t specifically address eosinophilic
More from news
Approximately 7 fully matching, plus 21 partially matching documents found.
Latest from PMHub
-
RWE Blog 1: Real-world challenges and real-world data
A meta-analysis of real-world studies where omalizumab treatment of chronic idiopathic urticaria met or improved on both efficacy and safety predictions from the RCTs.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine
- Gut instincts lead Takeda to GI pipeline success
- How will the events and exhibitions industry change post-Coronavirus?
- Novavax reports promising phase 1 results for coronavirus vaccine
- Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops
- A new era for patient services?
- Live Webinar: Examining the Interface Between Healthcare & Society
- Novavax reports promising phase 1 results for coronavirus vaccine
- Merck enters agreement with Hanmi for investigational NASH drug
- AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
- Virtual Engagement At Porterhouse: Reflections on the past few months
- July 2020: diversity and inclusion in clinical trials round-up
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- Virtual Engagement At Porterhouse: Reflections on the past few months
- ...
- July 2020: diversity and inclusion in clinical trials round-up
- COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
- Medical Device Clinical Trials 2020
- In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Quick links
Infographics
